Genprex, Inc. Update: Nasdaq Listing Status

Genprex, Inc. is a clinical-stage gene therapy company focused on developing cancer treatments, including its lead product, REQORSA® Immunogene Therapy, for lung cancers. As a company that is not yet profitable, Genprex relies on selling stock to fund its ongoing research and clinical trials.

1. What happened?

On June 10, 2026, the Nasdaq Stock Market notified Genprex that it failed to meet the minimum price requirement. Its stock closed below $1.00 per share for 30 consecutive business days. While Nasdaq typically grants a 180-day grace period to fix this, Genprex is ineligible because it performed a reverse stock split within the last three fiscal years.

2. Why does this matter?

This notice is a significant warning sign. If the stock is removed from the Nasdaq, it would move to the Over-the-Counter (OTC) markets. These markets generally have fewer buyers and sellers, wider gaps between buy and sell prices, and less regulatory oversight. Furthermore, delisting could trigger defaults on existing loans, limit the company’s ability to raise necessary capital, and negatively impact the stock’s value.

3. What happens next?

Genprex has requested a hearing before a Nasdaq panel to appeal the delisting.

• The "Stay": Requesting a hearing pauses the delisting process. Shares will continue to trade on the Nasdaq while the panel reviews the case.
• The Strategy: The company is exploring ways to regain compliance, which may include another reverse stock split.
• The Goal: To remain on the Nasdaq, the company must demonstrate a plan to keep its share price at or above $1.00 for a period determined by the panel.

4. What should investors know?

• The Hearing is Not a Guarantee: The hearing request buys time, but it does not guarantee a win. The panel can still choose to delist the company if they find the proposed plan insufficient.
• The "Reverse Split" Risk: A reverse stock split is a mechanical change that reduces the number of shares while raising the price per share. It does not improve the company’s financial health, profitability, or clinical trial progress. Repeated splits often signal financial distress and can lead to further downward pressure on the stock price.
• Focus on Fundamentals: Ultimately, Genprex’s long-term value depends on its research pipeline. To make an informed decision, review the company’s SEC filings (specifically Form 8-K and 10-Q) to track their "burn rate"—how fast they are spending cash—and the progress of their clinical trials. These factors are the true drivers of the company’s ability to survive and attract future investment.

Disclaimer: I am an AI, not a financial advisor. Stock market investments carry risk. Always do your own research or consult with a qualified financial professional before making investment decisions.